Cargando…

Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer

OBJECTIVES: Loss of tumor‐inherent type I interferon (IFN) signalling has been closely linked to accelerated metastatic progression via decreased immunogenicity and antitumor immunity. Previous studies in murine models of triple‐negative breast cancer (TNBC) demonstrate that systemic IFN inducers ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanker, Damien J, Spurling, Alex J, Brockwell, Natasha K, Owen, Katie L, Zakhour, Jasmine M, Robinson, Tina, Duivenvoorden, Hendrika M, Hertzog, Paul J, Mullins, Stefanie R, Wilkinson, Robert W, Parker, Belinda S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520806/
https://www.ncbi.nlm.nih.gov/pubmed/33005415
http://dx.doi.org/10.1002/cti2.1177
_version_ 1783587850604773376
author Zanker, Damien J
Spurling, Alex J
Brockwell, Natasha K
Owen, Katie L
Zakhour, Jasmine M
Robinson, Tina
Duivenvoorden, Hendrika M
Hertzog, Paul J
Mullins, Stefanie R
Wilkinson, Robert W
Parker, Belinda S
author_facet Zanker, Damien J
Spurling, Alex J
Brockwell, Natasha K
Owen, Katie L
Zakhour, Jasmine M
Robinson, Tina
Duivenvoorden, Hendrika M
Hertzog, Paul J
Mullins, Stefanie R
Wilkinson, Robert W
Parker, Belinda S
author_sort Zanker, Damien J
collection PubMed
description OBJECTIVES: Loss of tumor‐inherent type I interferon (IFN) signalling has been closely linked to accelerated metastatic progression via decreased immunogenicity and antitumor immunity. Previous studies in murine models of triple‐negative breast cancer (TNBC) demonstrate that systemic IFN inducers are effective antimetastatic agents, via sustained antitumor CD8(+) T‐cell responses. Repeated systemic dosing with recombinant IFNs or IFN inducers is associated with significant toxicities; hence, the use of alternate intratumoral agents is an active area of investigation. It is critical to investigate the impact of intratumoral agents on subsequent metastatic spread to predict clinical impact. METHODS: In this study, the local and systemic impact of the intratumoral Toll‐like receptor (TLR) 7/8 agonist 3M‐052 alone or in combination with anti‐PD1 was evaluated in metastatic TNBC models. The IFN‐α receptor (IFNAR1) blocking antibody, MAR1‐5A3, along with immune‐deficient mice and ex vivo assays are utilised to examine the key targets of this agent that are critical for an antimetastatic response. RESULTS: Single intratumoral administration of 3M‐052 reduced mammary tumor growth, induced a T‐cell‐inflamed tumor microenvironment (TME) and reduced metastatic spread to lung. Metastasis suppression was reliant on IFN signalling and an antitumor immune response, in contrast to primary tumor growth inhibition, which was retained in NSG and CD8(+) T‐cell‐depleted mice. 3M‐052 action was demonstrated via dendritic cell activation and production of type I IFN and other pro‐inflammatory cytokines to initiate a T‐cell‐inflamed TME and promote tumor cell antigen presentation. CONCLUSION: This work supports neoadjuvant TLR agonist‐based immunotherapeutics as realistic options for immune activation in the TME and long‐term metastatic protection in TNBC.
format Online
Article
Text
id pubmed-7520806
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75208062020-09-30 Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer Zanker, Damien J Spurling, Alex J Brockwell, Natasha K Owen, Katie L Zakhour, Jasmine M Robinson, Tina Duivenvoorden, Hendrika M Hertzog, Paul J Mullins, Stefanie R Wilkinson, Robert W Parker, Belinda S Clin Transl Immunology Original Articles OBJECTIVES: Loss of tumor‐inherent type I interferon (IFN) signalling has been closely linked to accelerated metastatic progression via decreased immunogenicity and antitumor immunity. Previous studies in murine models of triple‐negative breast cancer (TNBC) demonstrate that systemic IFN inducers are effective antimetastatic agents, via sustained antitumor CD8(+) T‐cell responses. Repeated systemic dosing with recombinant IFNs or IFN inducers is associated with significant toxicities; hence, the use of alternate intratumoral agents is an active area of investigation. It is critical to investigate the impact of intratumoral agents on subsequent metastatic spread to predict clinical impact. METHODS: In this study, the local and systemic impact of the intratumoral Toll‐like receptor (TLR) 7/8 agonist 3M‐052 alone or in combination with anti‐PD1 was evaluated in metastatic TNBC models. The IFN‐α receptor (IFNAR1) blocking antibody, MAR1‐5A3, along with immune‐deficient mice and ex vivo assays are utilised to examine the key targets of this agent that are critical for an antimetastatic response. RESULTS: Single intratumoral administration of 3M‐052 reduced mammary tumor growth, induced a T‐cell‐inflamed tumor microenvironment (TME) and reduced metastatic spread to lung. Metastasis suppression was reliant on IFN signalling and an antitumor immune response, in contrast to primary tumor growth inhibition, which was retained in NSG and CD8(+) T‐cell‐depleted mice. 3M‐052 action was demonstrated via dendritic cell activation and production of type I IFN and other pro‐inflammatory cytokines to initiate a T‐cell‐inflamed TME and promote tumor cell antigen presentation. CONCLUSION: This work supports neoadjuvant TLR agonist‐based immunotherapeutics as realistic options for immune activation in the TME and long‐term metastatic protection in TNBC. John Wiley and Sons Inc. 2020-09-28 /pmc/articles/PMC7520806/ /pubmed/33005415 http://dx.doi.org/10.1002/cti2.1177 Text en © 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Zanker, Damien J
Spurling, Alex J
Brockwell, Natasha K
Owen, Katie L
Zakhour, Jasmine M
Robinson, Tina
Duivenvoorden, Hendrika M
Hertzog, Paul J
Mullins, Stefanie R
Wilkinson, Robert W
Parker, Belinda S
Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer
title Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer
title_full Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer
title_fullStr Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer
title_full_unstemmed Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer
title_short Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer
title_sort intratumoral administration of the toll‐like receptor 7/8 agonist 3m‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520806/
https://www.ncbi.nlm.nih.gov/pubmed/33005415
http://dx.doi.org/10.1002/cti2.1177
work_keys_str_mv AT zankerdamienj intratumoraladministrationofthetolllikereceptor78agonist3m052enhancesinterferondriventumorimmunogenicityandsuppressesmetastaticspreadinpreclinicaltriplenegativebreastcancer
AT spurlingalexj intratumoraladministrationofthetolllikereceptor78agonist3m052enhancesinterferondriventumorimmunogenicityandsuppressesmetastaticspreadinpreclinicaltriplenegativebreastcancer
AT brockwellnatashak intratumoraladministrationofthetolllikereceptor78agonist3m052enhancesinterferondriventumorimmunogenicityandsuppressesmetastaticspreadinpreclinicaltriplenegativebreastcancer
AT owenkatiel intratumoraladministrationofthetolllikereceptor78agonist3m052enhancesinterferondriventumorimmunogenicityandsuppressesmetastaticspreadinpreclinicaltriplenegativebreastcancer
AT zakhourjasminem intratumoraladministrationofthetolllikereceptor78agonist3m052enhancesinterferondriventumorimmunogenicityandsuppressesmetastaticspreadinpreclinicaltriplenegativebreastcancer
AT robinsontina intratumoraladministrationofthetolllikereceptor78agonist3m052enhancesinterferondriventumorimmunogenicityandsuppressesmetastaticspreadinpreclinicaltriplenegativebreastcancer
AT duivenvoordenhendrikam intratumoraladministrationofthetolllikereceptor78agonist3m052enhancesinterferondriventumorimmunogenicityandsuppressesmetastaticspreadinpreclinicaltriplenegativebreastcancer
AT hertzogpaulj intratumoraladministrationofthetolllikereceptor78agonist3m052enhancesinterferondriventumorimmunogenicityandsuppressesmetastaticspreadinpreclinicaltriplenegativebreastcancer
AT mullinsstefanier intratumoraladministrationofthetolllikereceptor78agonist3m052enhancesinterferondriventumorimmunogenicityandsuppressesmetastaticspreadinpreclinicaltriplenegativebreastcancer
AT wilkinsonrobertw intratumoraladministrationofthetolllikereceptor78agonist3m052enhancesinterferondriventumorimmunogenicityandsuppressesmetastaticspreadinpreclinicaltriplenegativebreastcancer
AT parkerbelindas intratumoraladministrationofthetolllikereceptor78agonist3m052enhancesinterferondriventumorimmunogenicityandsuppressesmetastaticspreadinpreclinicaltriplenegativebreastcancer